European Companies Search Engine
EU funding (€12M): A clinical research network to improve the management of Monkeypox virus disease Hor5 Aug 2022 EU Research and Innovation programme "Horizon"
Overview
Text
A clinical research network to improve the management of Monkeypox virus disease
The 2022 Monkeypox outbreak is unprecedented in scale and cases are still active in South America and starting to appear in South-East Asia. Many questions about Monkeypox virus disease remain unanswered to this day, particularly concerning the management of patients. MPX-RESPONSE aims to increase our knowledge of the monkeypox virus disease, to improve its therapeutic management and to further inform public health policies and guidelines through four Work Packages (WP). WP2 (MOSAIC) will assess clinical and virological outcomes of Monkeypox patients treated or not with antiviral drugs, focusing treatment on the most severe cases. WPs 3 and 4 will conduct randomized clinical trials (RCT) with the most promising antiviral therapy, tecovirimat, targeting patients in Europe (WP3-EPOXI) and globally in collaboration with WHO (WP4-UNITY); particularly in mild and moderate cases. A common primary outcome will be shared between the two RCTs and EPOXI will include additional objectives regarding pharmacological, immunological and virological outcomes in six to ten EU/EEA countries and fulfill in particular EMA requirements for treatment authorisation. A continuous systematic review and individual patient meta-analysis will summarize all randomized evidence of the interventions for monkeypox. Finally, the project will make sure that acquired knowledge is integrated into public health policies and guidelines and that adequate messages are shared with the general public and high-risk populations with the help of patients’ representatives and associations (WP1-COORDINATE). To accomplish these objectives, MPX-RESPONSE will build on the expertise and networks of multiples partners including Ecraid and EU-RESPONSE and will reinforce and broaden Europe’s capacity to respond rapidly to public health emergencies.
Funded Companies:
| Company name | Funding amount |
| Les Hopitaux Universitaires DE Geneve | ? |
| Assistance Publique Hopitaux de Paris | €590,769 |
| Erasmus Universitair Medisch Centrum Rotterdam | €197,500 |
| Folkehelseinstituttet | €38,762 |
| Fundacao Oswaldo Cruz | €600,000 |
| Fundacion Huesped | €300,000 |
| Inserm Transfert SA | €335,123 |
| Institut National de la Sante et de la Recherche Medicale | €1,501,247 |
| Oslo Universitetssykehus HF | €827,875 |
| Pandemic Preparedness Platform for Health AND Emerging Infections Response | €2,820,000 |
| Servicio Madrileno de Salud | €145,000 |
| Stichting European Clinical Research Alliance ON Infectious Diseases | €2,546,273 |
| Universita Degli Studi Di Verona | €361,370 |
| Universitair Medisch Centrum Utrecht | €1,393,827 |
| Universiteit Antwerpen | €342,254 |
Source: https://cordis.europa.eu/project/id/101115188
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Les hôpitaux universitaires de Genève, Geneva, Switzerland.